Gerresheimer’s Two-Speed Recovery: Insider Confidence Meets Cash Flow Strain

Gerresheimer rebounds 80% from low but faces negative cash flow, a recent accounting scandal, and a critical US subsidiary sale to refinance debt.

When a stock has clawed back more than 80 percent from its 52-week low, the natural instinct is to call a turnaround. For Gerresheimer, the Düsseldorf-based specialist in pharmaceutical and cosmetic packaging, that recovery from February’s trough of €14.90 to Tuesday’s close of €27.28 tells only part of the story. The fuller picture is one of a company that has just cleared an accounting scandal, secured its audited financial statements, and is now racing to sell a US subsidiary before its cash reserves run dry.

The numbers that matter most right now are not the share price gains but the cash flow projections. Gerresheimer expects free cash flow of between minus €50 million and minus €100 million for 2026, a figure worsened by a reduction in factoring volumes. That negative trajectory makes the planned sale of its American unit Centor Inc. far more than a portfolio tidying exercise — it is the linchpin of a broader refinancing strategy that management aims to complete before year-end.

The Accounting Cleanup That Shook a Year

Gerresheimer’s 12-month decline of 43.3 percent was not driven by industry headwinds. It was a self-inflicted crisis of confidence rooted in corrections under IAS 8, following investigations into revenue recognition from bill-and-hold arrangements for the 2024 and 2025 financial years. The company has since abandoned that accounting method, drawn personnel consequences, and strengthened its compliance framework. In late June, it finally published audited annual and consolidated accounts for 2025 — a milestone that formally closes the chapter on the accounting uncertainty.

The audited figures showed group revenue rising 16.6 percent to €2.321 billion, with adjusted EBITDA reaching €384 million. Yet the clean audit opinion did not trigger a rally. On the day of publication, the stock slipped 2.78 percent, reflecting a market that is now focused on what comes next rather than what has been resolved.

A Cautious Outlook and a Tight Window

For the current financial year, Gerresheimer has tempered expectations. Revenue is now forecast to land in the lower half of the €2.3 billion to €2.4 billion range, while the adjusted EBITDA margin is seen at 17 to 18 percent. The company had already secured an agreement with its lenders in April to extend the deadline for audited statements until the end of September 2026, and its annual general meeting has been scheduled for September 1.

The strategic focus has shifted decisively to the balance sheet. The Centor disposal, mandated to Morgan Stanley in February, is expected to close this year and will be used to reduce net financial debt. Until that deal is completed, the negative free cash flow projection hangs over every other positive development.

Insiders and Institutions Place Their Bets

While the company was untangling its accounting issues, several investors were quietly building positions. In late April, entities linked to supervisory board member Klaus Röhrig — AOC Gecko S.à r.l. and the Active Ownership Fund — purchased shares worth approximately €12.7 million at €24.04 apiece. In mid-June, fellow board member Rudolf Schneider added to his own holdings. These insider purchases, totaling a meaningful vote of confidence from those closest to the restructuring, were followed by reports that Goldman Sachs had increased its stake during the first half of the year, a move widely interpreted as endorsement of the newly established transparency.

Operational Progress Beyond the Numbers

Away from the financial restructuring, Gerresheimer is pushing ahead with technology and sustainability initiatives. In mid-July, the group unveiled its “Digital Mold” technology, designed to cut development times for injection moulding tools used in medical technology. Earlier in the month, it published its first voluntary sustainability report, fully aligned with the Corporate Sustainability Reporting Directive, and commissioned a new photovoltaic installation at its Pfreimd site to boost energy self-sufficiency.

These operational steps are encouraging, but they do not yet change the arithmetic. The company’s market capitalisation has shrunk to roughly €1 billion — a fraction of its former value — and the path back to investment-grade credibility runs through the Centor sale and the refinancing that must follow it. For Gerresheimer, the next few months will determine whether the recovery from the February low becomes a genuine new chapter or merely a technical bounce before the next test.